The number of new AEDs has significantly
increased in the last 20 years, effectively doubling the
number of anticonvulsants available for physicians to
prescribe. Whilst the efficacy of new molecules in
controlling seizures has not dramatically increased,
safety and tolerability profiles are significantly better
than for the older AEDs. Many of the new drugs
have novel mechanisms of action and exhibit fewer
drug-interactions.